<tei>
    <teiHeader>
        <fileDesc xml:id="_0"/>
    </teiHeader>
    <text xml:lang="en">
        <listBibl>

        Boxes<lb/> 
        <bibl>Box 1. Drug safety monitoring and consumer protection ......................................................................... 12<lb/> </bibl>
<bibl>Box 2. Drug coverage in selected provinces and in the federal Non-insured Health Benefits programme20<lb/> Box 3. Formulary listing processes used in selected drug coverage schemes........................................... 23<lb/> </bibl>
<bibl>Box 4. Evidence of the impact of formulary listing on consumption patterns.......................................... 27<lb/> </bibl>
<bibl>Box 5. Cost-sharing arrangements in selected provincial drug plans ....................................................... 33<lb/> </bibl>
<bibl>Box 6. Canadian evidence on the impact of cost-sharing on drug use...................................................... 34<lb/> </bibl>
<bibl>Box 7. Developing a new national strategy for pharmaceuticals in Canada ............................................. 37<lb/> </bibl>
<bibl>Box 8. Cross-border trade ......................................................................................................................... 55<lb/> </bibl>
<bibl>Box 9. Methods used in PMPRB price comparisons ................................................................................ 73<lb/> REFERENCES<lb/> </bibl>
<bibl>Ackroyd-Stolarz, S., N. Hartnell, N.J. MacKinnon (2006), &quot; Demystifying medication safety: Making sense<lb/> of terminology &quot; , Research in Social and Administrative Pharmacy, Vol. 2, pp.280-289.<lb/> </bibl>
<bibl>Anis, A. and Q. Wen (1998), &quot; Price regulation of pharmaceuticals in Canada &quot; , Journal of Health<lb/> Economics, Vol. 17, pp. 21-38.<lb/> </bibl>
<bibl>Anis, A., D. Guh, X.H. Wang (2001), &quot; A Dog&apos;s Breakfast: Prescription drug coverage varies widely across<lb/> Canada &quot; , Medical Care, Vol. 39, No. 4. pp. 315-326.<lb/> </bibl>
<bibl>Anis, A., D. Guh, D. Lacaille, C. Marra, A. Rashidi, X. Li, J. Esdaile (2005), &quot; When patients have to pay a<lb/> share of drug costs: effects on frequency of physician visits, hospital admissions and filling of<lb/> prescriptions &quot; , Canadian Medical Association Journal, Vol. 173, No. 11, pp. 1335-1340.<lb/> </bibl>
<bibl>Applied Management, Fraser Group and Tristat Resources. (2000), Canadians&apos; access to insurance for<lb/> prescription medicines, Volumes 1: Range and extent of coverage, submitted to Health Canada.<lb/> </bibl>
<bibl>Applied Management, Fraser Group and Tristat Resources (2000), Canadians&apos; access to insurance for<lb/> prescription medicines, Volumes 2: The un-insured and under-insured, submitted to Health Canada.<lb/> </bibl>
<bibl>Arthur, M., M. Hunt, and K. Lee (2006), How Common are the Provincial/ Territorial Public Drug<lb/> Formularies?, Poster Exhibition at Toward a National Pharmaceuticals Strategy, Vancouver, B.C.,<lb/> Canadian Institute for Health Information, February 9-10, 2006.<lb/> </bibl>
<bibl>Auditor General of British Columbia (2006), Managing PharmaCare: slow progress toward Cost-effective<lb/> drug use and a sustainable program, British Columbia Ministry of Health.<lb/> </bibl>
<bibl>Auditor General of Canada (2004), &quot; Chapter 4: Management of Federal Drug Benefit Programs &quot; , Report of<lb/> the Auditor General to the House of Commons, November 2004.<lb/> </bibl>
<bibl>Auditor General of Ontario (2001), &quot; Audit of the Drug Programs Activity of the Ministry of Health and<lb/> Long-Term Care &quot; , Auditor Annual report, pp. 189-221<lb/> </bibl>
<bibl>BIOTECanada (2004), Biotecanada orphan drug policy, Policy paper, pp. 6.<lb/> </bibl>
<bibl>British Columbia College of Pharmacists (2004), &quot; Drug interchangeability update &quot; , FYI, Vol.3, No.1, pp.<lb/> 4.<lb/> </bibl>
<bibl>British Columbia Ministry of Health (2004), PharmaCare Trends 2003, Victoria.<lb/> </bibl>
<bibl>Bruce, S., H. Prior, A. Katz, M. Taylor, S. Latosinsky, P. Martens, C. De Coster, M. Brownell, R. Soodeen<lb/> and C. Steinbach (2006), Application of Patient Safety Indicators in Manitoba: A First Look,<lb/> Manitoba Centre for Health Policy.<lb/> </bibl>
<bibl>Campbell C., C. Cooke, S. Weerasinghe, I. Sketris, P. McLean-Veysey, C. Skedgel (2003), &quot; Topical<lb/> corticosteroid prescribing patterns following changes in drug benefit status &quot; , The Annals of<lb/> Pharmacotherapy, Vol. 37, pp. 787-793.<lb/> </bibl>
<bibl>Canadian Organization for Rare Disorders (2005), Towards a Canadian orphan drug policy.<lb/> </bibl>
<bibl>Canadian Institute for Health Information – CIHI, (2005), Drug expenditure in Canada 1985-2004,<lb/> Ottawa.<lb/> </bibl>
<bibl>Canadian Institute for Health Information – CIHI, (2006), Drug expenditure in Canada 1985-2005,<lb/> Ottawa.<lb/> </bibl>
<bibl>Canadian Medical Association (2003), &quot; Principles for providing information about prescription drugs to<lb/> consumers &quot; , statement approved by the Canadian Medical Association Board of Directors, March<lb/> 2003.<lb/> </bibl>
<bibl>Canadian Medical Association (2002), &quot; Direct-to-Consumer Advertising Policy Statement &quot; , statement<lb/> approved by the CMA Board of Directors, September 2002.<lb/> </bibl>
<bibl>Cancer Advocacy Coalition of Canada (2006), Report Card 2005, Vol. 8, pp. 26-38.<lb/> </bibl>
<bibl>Cassels, A. (2002), &quot; Paying for what works: BC&apos;s experience with the Reference Drug Program as a model<lb/> for rational policy making &quot; , Vancouver: Canadian Centre for Policy Alternatives—BC Office.<lb/> </bibl>
<bibl>Commission on the Future of Health Care in Canada (2002), &quot; Chapter 9: prescription drugs &quot; , Building on<lb/> Values (Final report), pp. 189-210.<lb/> </bibl>
<bibl>Conseil du medicament (2005), Rapport annuel de gestion 2004-2005, Gouvernement du Québec.<lb/> </bibl>
<bibl>Conseil du medicament (2006), Rapport annuel de gestion 2005-2006, Gouvernement du Québec.<lb/> </bibl>
<bibl>Cooke C., L. Nissen, I. Sketris and S. Tett. (2005), &quot; Quantifying the use of the statin antilipemic drugs:<lb/> comparisons and contrasts between Nova Scotia, Canada and Queensland, Australia &quot; , Clinical<lb/> Therapeutics, Vol. 27, No. 4, pp. 497-503.<lb/> </bibl>
<bibl>Danzon P.M. and M.F. Furukawa (2003), &quot; Prices and availability of pharmaceuticals: Evidence from nine<lb/> countries &quot; , Health Affairs, web exclusive, pp. W3.521-536.<lb/> </bibl>
<bibl>D&apos;Cruz J., W. Hejazi and G. Fleischmann (2005), &quot; Comparisons of retail prices of generic prescription<lb/> drugs in Canada vs. United States: A comprehensive study &quot; , A Report Prepared for the Canadian<lb/> Generic Pharmaceutical Association.<lb/> </bibl>
<bibl>EFPIA (European Federation of Pharmaceutical Industries and Associations) (2005), The Pharmaceutical<lb/> Industry in Figures, Key data – update 2005.<lb/> </bibl>
<bibl>Fraser Group/ Tristat Resources (2002), Drug expense coverage in the Canadian population: protection<lb/> from severe drug expenses.<lb/> </bibl>
<bibl>Gardner, D.M., B. Mintzes and A. Ostry (2003), &quot; Direct-to-consumer prescription drug advertising in<lb/> Canada: Permission by Default? &quot; Canadian Medical Association Journal, Vol. 169, No. 5, pp. 425-<lb/>427.<lb/> </bibl>
<bibl>Government of Canada (2004), &quot; Regulations amending the Food and Drug regulation (1390-data<lb/> protection) &quot; , Canada Gazette, Vol. 138, No. 50.<lb/> </bibl>
<bibl>Government of Canada (2004), &quot; Regulations amending the Patented Medicines (Notice of Compliance)<lb/> Regulations &quot; , Canada Gazette, Vol. 138, No. 50.<lb/> </bibl>
<bibl>Government of Canada. 39 th Parliament , 1 st Session Standing Committee on Health (HESA), Evidence<lb/> from meeting on Prescription Drugs House of Commons Standing Committee on Heath, 2006,<lb/> http://cmte.parl.gc.ca/cmte/CommitteePublication.aspx?SourceId=149490.<lb/> </bibl>
<bibl>Government of Canada (2005), &quot; Canada&apos;s winning secrets summary &quot; ,<lb/> www.investincanada.gc.ca/en/1031/Canada_s_Winning_Secrets_Report.html, accessed 26 May<lb/> 2006.<lb/> </bibl>
<bibl>Government of Ontario (2006), 2004/2005 Report Card for the Ontario Drug Benefit Program.<lb/> </bibl>
<bibl>Grégoire J.P., P. Macneil, K. Skilton, J. Moisan, D. Menon, P. Jacobs, E. McKenzie and B. Ferguson<lb/> (2001), &quot; Inter-provincial variation in Government drug formularies &quot; , Canadian Journal of Public<lb/> Health, Vol. 92, No. 4, pp. 307-312.<lb/> </bibl>
<bibl>Grootendorst, P &quot;Beneficiary Cost Sharing under Canadian Provincial Prescription Drug Benefit Programs:<lb/> History and Assessment,&quot; Canadian Journal of Clinical Pharmacology, Vol. 9, No. 2, pp. 79–99.<lb/> </bibl>
<bibl>Grootendorst, P., L. Dolovitch, A.M. Holbrook, A.R. Levy and B.J. O&apos;Brien (2001), &quot; The impact of<lb/> reference pricing of cardiovascular drugs on health care costs and health outcomes: Evidence from<lb/> British Columbia &quot; , Report for the Canadian Health Services Research Foundation.<lb/> </bibl>
<bibl>Grootendorst, P., J.K. Marshall, A.M. Holbrook, L.R. Dolovitch, B.J. O&apos;Brien and A.R. Levy (2005), &quot; The<lb/> impact of reference pricing of nonsteroidal anti-inflammatory agents on the use and costs of<lb/> analgesic drugs &quot; , Health Services Research, Vol. 40, pp. 1297-1317.<lb/> </bibl>
<bibl>Grootendorst, P. and D. Stewart, &quot; A re-examination of the impact of reference pricing on anti-hypertensive<lb/> drug plan expenditures in British Columbia &quot; , Health Economics, Vol.15, pp. 735–742.<lb/> </bibl>
<bibl>Health Canada (2004), Non-Insured Health Benefit Program – Annual report 2003/2004, Ottawa.<lb/> </bibl>
<bibl>Health Canada (2006), Regulatory Review of Pharmaceuticals, Biologics and Medical Devices 2005 -<lb/>Annual Summary of Performance, Ottawa.<lb/> </bibl>
<bibl>Hollis, A. and Law, S. (2004), &quot; A National Formulary for Canada &quot; , Canadian Public Policy, Vol. 30, No.<lb/> 4, pp. 445-452.<lb/> </bibl>
<bibl>IMS Health (2006), &quot; Prescription drug purchases by Canadian hospitals and pharmacies reach $16.57<lb/> billion in 2005 &quot; ,<lb/> www.imshealth.com/web/content/0,3148,77303623_63872702_77770096_77808854,00.html,<lb/> accessed 24 May 2006.<lb/> </bibl>
<bibl>IMS Health Canada (2006b), IMS Drug Monitor: Canada.<lb/> </bibl>
<bibl>IMS Health Canada (2006a), &quot; Prescription drug purchases by Canadian hospitals and pharmacies reach<lb/> $16.57 billion in 2005 &quot; , IMS Health (2006b)<lb/> </bibl>
<bibl>DELSA/HEA/WD/HWP(2006)4<lb/> </bibl>
<bibl>82<lb/> </bibl>
<bibl>Industry Canada – Life Sciences Branch (2006), &quot; Canadian pharmaceutical industry profile &quot; .<lb/> </bibl>
<bibl>Kaiser Family Foundation (2006), &quot; Exhibit 1.19: Retail Prescriptions Filled at Pharmacies by State:<lb/> Prescriptions Per Capita and Retail Prescription Sales, 2004 &quot; , Trends and Indicators in the<lb/> Changing Health Care Marketplace.<lb/> </bibl>
<bibl>Kephart G., I. Sketris, S. Bowles, M. Richard, C. Cooke (2005), &quot; Impact of criteria-based reimbursement<lb/> policy on the use of respiratory drugs delivered by nebuliser and health care services utilisation in<lb/> Nova Scotia, Canada &quot; , Pharmacotherapy, Vol. 25, No. 9, pp. 1248-1257.<lb/> </bibl>
<bibl>Legislative Assembly of Ontario (2006), Bill 102: An Act to amend the Drug Interchangeability and<lb/> Dispensing Fee Act and the Ontaro Benefit Act, 30 pages.<lb/> </bibl>
<bibl>Lexchin J. (2006), &quot; A comparison of new drug availability in Canada and the United States and potential<lb/> therapeutic implications of differences &quot; , Health Policy, Vol. 79, No. 2-3, pp. 214-220.<lb/> </bibl>
<bibl>Luffman J. (2005), &quot; Out-of-pocket spending on prescription drugs &quot; , Perspectives on Labour and Income,<lb/> Vol. 17, No. 4, pp 5-13.<lb/> </bibl>
<bibl>Marchildon, G.P. (2005), Health Systems in Transition: Canada, Copenhagen, WHO, Regional Office for<lb/> Europe on behalf of the European Observatory on Health Systems and Policies.<lb/> </bibl>
<bibl>Marchildon, G.P. (2006), &quot; Federal pharmacare: prescription for an ailing federation? &quot; , Inroads, No. 18, pp.<lb/> 94-108.<lb/> </bibl>
<bibl>Marshall J.K., P.V. Grootendorst, B.J. O&apos;Brien, L.R. Dolovitch, A.M. Holbrook and A.R. Levy (2002),<lb/> &quot; Impact of reference-based pricing for histamine-2 receptor antagonists and restricted access to<lb/> proton pump inhibitors in British Columbia &quot; , Canadian Medical Association Journal, Vol. 166, No.<lb/> 13, pp. 1655-1662<lb/> </bibl>
<bibl>McIntosh T. (2004), &quot; National pharmacare proposal &quot; , Health Policy Monitor, Bertelsmann Foundation,<lb/> Survey No.4.<lb/> </bibl>
<bibl>McKenzie, K.J. (2005), &quot; Tax Subsidies for R&amp;D in Canadian Provinces, &quot; Canadian Public Policy, Vol.<lb/> XXXI, No. 1, pp. 29-44.<lb/> </bibl>
<bibl>McMahon, M., S. Morgan, and C. Mitton (2006), &quot; The common drug review: A NICE start for Canada? &quot; ,<lb/> Health Policy, Vol. 77, No. 3, pp. 339-351.<lb/> </bibl>
<bibl>Mintzes, B., M.L. Barer, R.L. Kravitz, K. Bassett, J. Lexchin, A. Kazanjian, R.G. Evans, R. Pan, and S.A.<lb/> Marion (2003), &quot; How does direct-to-consumer advertising (DTCA) affect prescribing? A survey in<lb/> primary care environments with and without DTCA &quot; , Canadian Medical Association Journal, Vol.<lb/> 169. No. 5, pp. 405-412.<lb/> </bibl>
<bibl>Morgan, S., M. Barer, and J.D. Agnew (2003), &quot; Whither Seniors&apos; Pharmacare: Lessons from (and for)<lb/> Canada &quot; , Health Affairs, Vol. 22, No. 3, pp. 49-59.<lb/> </bibl>
<bibl>Morgan S., A. Kozyrskyj, C. Metge, N. Roos and M.Dahl (2003), Pharmaceuticals: Therapeutic<lb/> Interchange and Pricing Policies, Manitoba Centre for Health Policy, Manitoba Health.<lb/> </bibl>
<bibl>Morgan, S. (2004), &quot; Drug spending in Canada: recent trends and causes &quot; , Medical Care, Vol. 42, No. 7,<lb/> pp. 635-642.<lb/> </bibl>
<bibl>Morgan, S., K. Basset, B. Mintzes (2004), &quot; Outcome-based drug coverage in British Columbia &quot; , Health<lb/> Affairs, Vol. 23, No. 3, pp. 269-276.<lb/> </bibl>
<bibl>Morgan, S., M. McMahon, J. Lam, D. Mooney, and C. Raymond (2005), The Canadian Rx Atlas, The<lb/> Centre for Health Services and Policy Research, Vancouver.<lb/> </bibl>
<bibl>MSSS (Ministère de la santé et des services sociaux) (2004), Politique du médicament, Document de<lb/> consultation.<lb/> </bibl>
<bibl>Murphy A., N. MacKinnon, P. Flanagan, S. Bowles and I. Sketris (2005), &quot; Pharmacists&apos; participation in an<lb/> inhaled respiratory medication program: Reimbursement of professional fees &quot; , Annals of<lb/> Pharmacotherapy, Vol. 39, pp. 655-661.<lb/> </bibl>
<bibl>National Institute for Health Care Management Foundation (2001), Prescription Drugs and Mass Media<lb/> Advertising, 2000, The National Institute for Health Care Management Research and Educational<lb/> Foundation, Washington.<lb/> </bibl>
<bibl>OECD (2005), OECD Health Data 2005: Statistics and Indicators for 30 Countries, Paris.<lb/> </bibl>
<bibl>OECD (2006), OECD Economic Survey: Canada, Paris.<lb/> </bibl>
<bibl>Ontario Ministry of Health and Long Term Care (2006), 2004/05 Report Card for the Ontario Drug<lb/> Benefit Program.<lb/> </bibl>
<bibl>Palmer d&apos;Angelo Consulting Inc. (2002), Generic drug prices: A Canada US comparison.<lb/> </bibl>
<bibl>Palumbo B.F. (2004) &quot; Status of legislation on pharmaceutical reimportation: The relevance of IP laws to<lb/> reimportation &quot; , Managed Care, Vol. 13, No.6, pp. 3-6.<lb/> </bibl>
<bibl>PICTF (Pharmaceutical Industry Competitiveness Task Force) (2006), Competitiveness and performance<lb/> indicators 2005.<lb/> </bibl>
<bibl>PMPRB (Patented Medicine Prices Review Board) (2001), Provincial drug plans overview reports –<lb/> Pharmaceutical Trends 1995/96 – 1999/00, Report prepared by PMPRB for the F/P/T Working<lb/> group on drug prices, Ottawa.<lb/> </bibl>
<bibl>PMPRB (Patented Medicine Prices Review Board) (2002), A study of the prices of the Top selling multiple<lb/> source medicines in Canada, prepared by PMPRB for the F/P/T Working group on drug prices,<lb/> Ottawa.<lb/> </bibl>
<bibl>PMPRB (Patented Medicine Prices Review Board) (2002), Verification of foreign patented drug prices,<lb/> Ottawa.<lb/> </bibl>
<bibl>PMPRB (Patented Medicine Prices Review Board) (2002a), Foreign Price trends for patented medicines,<lb/> Ottawa.<lb/> </bibl>
<bibl>PMPRB (Patented Medicine Prices Review Board) (2002b), A comparison of pharmaceutical Research &amp;<lb/> Development Spending in Canada and selected countries, Ottawa.<lb/> </bibl>
<bibl>PMPRB (Patented Medicine Prices Review Board) (2003), Top selling non-patented single source drug<lb/> products: international comparison 1998/1999, prepared by PMPRB for the F/P/T Working group<lb/> on drug prices, Ottawa.<lb/> </bibl>
<bibl>PMPRB (Patented Medicine Prices Review Board) (2003) Compendium of Guidelines, Policies and<lb/> procedures, Ottawa.<lb/> </bibl>
<bibl>PMPRB (Patented Medicine Prices Review Board) (2005a), Annual Report 2004, Ottawa.<lb/> </bibl>
<bibl>PMPRB (Patented Medicine Prices Review Board) (2005b), Budget impact analysis guidelines: Needs<lb/> assessment, Ottawa.<lb/> </bibl>
<bibl>PMPRB (Patented Medicine Prices Review Board) (2005c), The impact upon public drug plans of changes<lb/> in drug distribution, Ottawa.<lb/> </bibl>
<bibl>PMPRB (Patented Medicine Prices Review Board) (2006a), Annual Report 2005, Ottawa.<lb/> </bibl>
<bibl>PMPRB (Patented Medicine Prices Review Board) (2006b), Pharmaceutical trends – Overview report,<lb/> Analytical Study Series, Ottawa.<lb/> </bibl>
<bibl>PMPRB (Patented Medicine Prices Review Board) (2006c), Non-patented prescription drug prices<lb/> reporting – Canadian and Foreign Price trends, Ottawa.<lb/> </bibl>
<bibl>PMPRB (Patented Medicine Prices Review Board) (2006d), Discussion guide for the consultations on the<lb/> Board&apos;s excessive price guidelines, Ottawa.<lb/> </bibl>
<bibl>Paterson M., K. Bassett, M. Mamdani, J. Wright, G. Naglie, A. Laupacis, G. Anderson (2003), &quot; What<lb/> effects do provincial drug plan policies for new drugs have on patterns of use and cost? &quot; , Institute<lb/> for Clinical Evaluative Science.<lb/> </bibl>
<bibl>PausJenssen A.M., P.A. Singer, A.S. Detsky. (2003), &quot; Ontario&apos;s formulary committee: How<lb/> recommendations are made? &quot; , Pharmacoeconomics, Vol. 21, No. 4, pp. 285-294.<lb/> </bibl>
<bibl>Pharmaceutical Advertising Advisory Board (2006), PAAB Review.<lb/> </bibl>
<bibl>Priest L. (2006), &quot; Drugs makers expected to shun Canada &quot; , The Globe and Mail, June 23, 2006.<lb/> </bibl>
<bibl>Public Policy Forum (2006), Generic Pharmaceuticals and Sector Development -Industry Challenges and<lb/> Potential Solutions.<lb/> </bibl>
<bibl>Schneeweiss, S, A.M. Walker, R.J. Glynn, M. Maclure, C. Dormuth, and S.B. Soumerai (2002a),<lb/> &quot; Outcome of reference pricing for angiotensin-converting enzyme inhibitors &quot; , New England Journal<lb/> of Medicine, Vol. 346, No. 11, pp. 822-829.<lb/> </bibl>
<bibl>Schneeweiss, S., S.B. Soumerai, R.J. Glynn, M. Maclure, C. Dormuth and A.M. Walker (2002b), &quot; Impact<lb/> of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization &quot; ,<lb/> Canadian Medical Association Journal, Vol. 166, No. 6, pp. 737-745.<lb/> </bibl>
<bibl>Schneeweiss S., S.B. Soumerai, M. Maclure, C. Dormuth, A.M. Walker, and R.J. Glynn (2003), &quot; Clinical<lb/> and economic consequences of reference pricing for dihydropyridine calcium channel blockers &quot; ,<lb/> Clinical Pharmacology &amp; Therapeutics, Vol. 74, pp. 388-400.<lb/> </bibl>
<bibl>Schneeweiss S., C. Dormuth, P. Grootendorst, S.B. Soumerai, and M. Maclure (2004), &quot; Net health plan<lb/> savings from reference pricing for angiotensin-converting enzyme inhibitors in elderly British<lb/> Columbia residents &quot; , Medical Care, Vol. 42, No. 7, pp. 653-660<lb/> </bibl>
<bibl>Schoen C., R. Osborn, P. Trang Huynh, M. Doty, K. Zapert, J. Peugh and K. Davis (2005), &quot; Taking the<lb/> pulse of health care systems: experiences of patients with health problems in six countries &quot; , Health<lb/> Affairs, Web-exclusive, pp. w5-509-525.<lb/> </bibl>
<bibl>Sketris I., C. Metge, J. Ross, M. MacCara, D. Comeau, G. Kephart and J. Blackburn J. (2004a), &quot; The use<lb/> of the World Health Organisation Anatomical Therapeutic Chemical/ Defined daily dose<lb/> methodology in Canada &quot; , Drug Information Journal, Vol. 38, pp. 1-13.<lb/> </bibl>
<bibl>Sketris I., C. Metge, Y. Schevchuk, D. Comeau, G. Kephart, J. Blackburn, M. MacCara and A. Laturnas<lb/> (March 2004b), &quot; Comparison of anti-infective drug use in elderly persons in Manitoba, Nova Scotia,<lb/> and Saskatchewan, Canada: Relationship to drug insurance reimbursement policies &quot; , The American<lb/> Journal of Geriatric Pharmacotherapy, Vol. 2, No. 1, pp. 24-35.<lb/> </bibl>
<bibl>Sketris, I., G. Kephart, D. Frail, C. Skedgel, and M. Allen (2004c), &quot; The effects of deinsuring<lb/> chlorpropamide on the prescribing of oral antihyperglycemics for Nova Scotia Seniors Pharmacare<lb/> beneficiaries &quot; , Pharmacotherapy, Vol. 24, No. 6, pp. 784-791.<lb/> </bibl>
<bibl>Sketris, I., G. Kephart, C. Cooke, C. Skedgel, P. McLean-Veysey (2005), &quot; Use of Physician Profiles to<lb/> influence prescribing of topical corticosteroids &quot; , Canadian Journal of Clinical Pharmacology, Vol.<lb/> 12, No. 2, pp. 186-197.<lb/> </bibl>
<bibl>Skinner B.J. (2004), Generic Drugopoly: Why Non-patented Prescription Drugs Cost More in Canada<lb/> than in the United States and Europe. The Fraser Institute, Vancouver.<lb/> </bibl>
<bibl>Skinner, B.J. (2005), Canada&apos;s Drug Price Paradox: The Unexpected Losses Caused by Government<lb/> Interference in Pharmaceutical Markets. Fraser Institute digital publication, The Fraser Institute,<lb/> Vancouver.<lb/> </bibl>
<bibl>Skinner, B.J. (2006), Price Controls, Patents, and Cross-Border Internet Pharmacies: Risks to Canada&apos;s<lb/> Drug Supply and International Trading Relations. Critical Issues Bulletin, The Fraser Institute,<lb/> Vancouver.<lb/> </bibl>
<bibl>Standing Senate Committee on Social Affairs (2002), Science and Technology, The Health of Canadians –<lb/> The Federal Role, Final Report, Chapter 7,<lb/> http://www.parl.gc.ca/37/2/parlbus/commbus/senate/Com-e/soci-e/rep-e/repoct02vol6-e.htm,<lb/> accessed May 2006.<lb/> </bibl>
<bibl>Smith M. (1993), Patent protection for pharmaceutical products, Government of Canada, Law and<lb/> Government Division, http://dsp-psd.pwgsc.gc.ca/Collection-R/LoPBdP/BP/bp354-e.htm, accessed<lb/> 1 May 2006.<lb/> </bibl>
<bibl>Statistics Canada (2006), &quot; Estimates of total spending on research and development in the health field in<lb/> Canada &quot; , Sciences Statistics, Service Bulletin, Vol. 30, No. 3.<lb/> </bibl>
<bibl>Tamblyn, R, R. Laprise, J.A. Hanley, M. Abrahamowicz, S. Scott, N. Mayo, J. Hurley, R. Grad, E.<lb/> Latimer, R. Perreault, P. McLeod, A. Huang, P. Larochelle and L. Mallet (2001), &quot; Adverse Events<lb/> Associated With Prescription Drug Cost-Sharing Among Poor and Elderly Persons &quot; , JAMA, Vol.<lb/> 285, No. 4, pp. 421-429<lb/> </bibl>
<bibl>University of Calgary (2004), A national formulary for Canada, working paper.<lb/> </bibl>
<bibl>DELSA/HEA/WD/HWP(2006)4<lb/> </bibl>
<bibl>86<lb/> </bibl>
<bibl>US Department of Commerce (2004), NAFTA 10 Years Later, International Trade Administration, Office<lb/> of Industry Trade Policy,<lb/> Vandergrift, M. and P. Kanavos (1997), &quot; Health policy versus industrial policy in the pharmaceutical<lb/> sector: the case of Canada &quot; , Health Policy, Vol. 41, pp. 241-260.<lb/> </bibl>
<bibl>Vekeman, G. (2005), &quot; L&apos;industrie pharmaceutique dans l&apos;Union Européenne &quot; , Statistiques en bref,<lb/> Industrie, commerce et services, Communautés Européennes.<lb/> </bibl>
<bibl>Wagner W.J. (2004), &quot; The Relevance of Intellectual Property Laws to Reimportation &quot; , Managed Care,<lb/> supplement, Vol. 13, No. 6 supplement, pp. 20-22<lb/> </bibl>
        <bibl><label>E.</label> Mossialos, M. Mrazek and T. Walley (eds.) (2004), &quot; Financial incentives and prescribing &quot; , in<lb/> Regulating Pharmaceuticals in Europe: Striving for Efficiency, Equity and Quality, Open University<lb/> Press, Maidenhead.<lb/> </bibl>
<bibl>Ward, C. (2004), &quot; Economic and Policy Implications of Reimportation: A Canadian Perspective, &quot;<lb/> Managed Care, Vol. 13. No. supplement 3, pp. 17-20.<lb/> </bibl>
<bibl>Wilson R. (2001) &quot; Quality improvement will require a major commitment &quot; , Hospital Quarterly, Vol. 4,<lb/> No. 3, pp. 20-24.<lb/> </bibl>
<bibl>DELSA/HEA/WD/HWP(2006)4<lb/> </bibl>
<bibl>87<lb/> OECD HEALTH WORKING PAPERS<lb/> Papers in this series can be found on the OECD website: www.oecd.org/els/health/workingpapers<lb/> No. 23 HEALTH CARE QUALITY INDICATORS PROJECT, CONCEPTUAL FRAMEWORK PAPER<lb/> (2006) Edward Kelley and Jeremy Hurst<lb/> No. 22 HEALTH CARE QUALITY INDICATORS PROJECT, INITIAL INDICATORS REPORT (2006)<lb/> Soeren Mattke, Edward Kelley, Peter Scherer, Jeremy Hurst, Maria Luisa Gil Lapetra and the<lb/> HCQI Expert Group Members<lb/> No. 21 THE SUPPLY OF PHYSICIANS IN OECD COUNTRIES (2006) Steven Simeons and Jeremy<lb/> Hurst<lb/> No. 20 CONSUMER DIRECTION AND CHOICE IN LONG-TERM CARE FOR OLDER PERSONS,<lb/> INCLUDING PAYMENTS FOR INFORMAL CARE: HOW CAN IT HELP IMPROVE CARE<lb/> OUTCOMES, EMPLOYMENT AND FISCAL SUSTAINABILITY? (2005) Jens Lundsgaard<lb/> No. 19 TACKLING NURSE SHORTAGES IN OECD COUNTRIES (2004) Steven Simoens, Mike<lb/> Villeneuve and Jeremy Hurst<lb/> No. 18 PRIVATE HEALTH INSURANCE IN THE NETHERLANDS. A CASE STUDY (2004) Nicole<lb/> Tapay and Francesca Colombo<lb/> No. 17 SKILL-MIX AND POLICY CHANGE IN THE HEALTH WORKFORCE: NURSES IN<lb/> ADVANCED ROLES (2004) James Buchan and Lynn Calman<lb/> No. 16 SHA-BASED NATIONAL HEALTH ACCOUNTS IN THIRTEEN OECD COUNTRIES: A<lb/> COMPARATIVE ANALYSIS (2004) Eva Orosz and David Morgan<lb/> No. 15 PRIVATE HEALTH INSURANCE IN OECD COUNTRIES: THE BENEFITS AND COSTS FOR<lb/> INDIVIDUALS AND HEALTH SYSTEMS (2004) Francesca Colombo and Nicole Tapay<lb/> No. 14 INCOME-RELATED INEQUALITY IN THE USE OF MEDICAL CARE IN 21 OECD<lb/> COUNTRIES (2004) Eddy van Doorslaer, Cristina Masseria and the OECD Health Equity<lb/> Research Group<lb/> No. 13 DEMENTIA CARE IN 9 OECD COUNTRIES: A COMPARATIVE ANALYSIS (2004) Pierre<lb/> Moise, Michael Schwarzinger, Myung-Yong Um and the Dementia Experts&apos; Group<lb/> No. 12 PRIVATE HEALTH INSURANCE IN FRANCE (2004) Thomas C. Buchmueller and Agnes<lb/> Couffinhal<lb/> No. 11 THE SLOVAK HEALTH INSURANCE SYSTEM AND THE POTENTIAL ROLE FOR PRIVATE<lb/> HEALTH INSURANCE: POLICY CHALLENGES (2004) Francesca Colombo and Nicole Tapay<lb/> No. 10 PRIVATE HEALTH INSURANCE IN IRELAND. A CASE STUDY (2004) Francesca Colombo and<lb/> Nicole Tapay<lb/> No. 9<lb/> HEALTH CARE SYSTEMS: LESSONS FROM THE REFORM EXPERIENCE (2003) Elizabeth<lb/> Docteur and Howard Oxley<lb/> No. 8<lb/> PRIVATE HEALTH INSURANCE IN AUSTRALIA. A CASE STUDY (2003) Francesca Colombo<lb/> and Nicole Tapay<lb/> No. 7<lb/> EXPLAINING WAITING-TIMES VARIATIONS FOR ELECTIVE SURGERY ACROSS OECD<lb/> COUNTRIES (2003) Luigi Siciliani and Jeremy Hurst<lb/> No. 6<lb/> TACKLING EXCESSIVE WAITING TIMES FOR ELECTIVE SURGERY: A COMPARISON OF<lb/> POLICIES IN 12 OECD COUNTRIES (2003) Jeremy Hurst and Luigi Siciliani</bibl>
        </listBibl>
    </text>
</tei>

